Last updated on January 2019

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).


Other Details:

  • Diagnosis of other autoimmune rheumatic disease. (i.e. RA, FMS, SLE)
  • History of known or suspected complete ankyloses of the spine.
  • Hx of recurrent herpes zoster/simplex >1 episode.
  • Hx of malignancy other than basal/squamous cell or cervical carcinoma in situ.
  • Hx of no more than two (2) TNF bDMARDs (i.e. enbrel, humira)
  • History/Exposure to Tofacitinib (Xeljanz)
  • bDMARD other than TNF Inhibitors (i.e. rituxan, Orencia)
  • Received recent live/attenuated vaccines.



Find a site near you

Start Over

The Center for Rheumatology and Bone Research

2730 University Blvd West, Suite 306 Wheaton, MD USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.